<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 19:05:20 -0700</creation_date>
  <update_date>2013-01-15 19:05:20 -0700</update_date>
  <accession>HMDBP02442</accession>
  <secondary_accessions>
    <accession>7936</accession>
  </secondary_accessions>
  <protein_type>Enzyme</protein_type>
  <synonyms>
  </synonyms>
  <gene_name>BCL2</gene_name>
  <general_function>Involved in regulation of apoptosis</general_function>
  <specific_function>Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1)</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB15360</accession>
      <name>Paclitaxel</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15378</accession>
      <name>Docetaxel</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15454</accession>
      <name>Rasagiline</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>process</category>
      <description>biological regulation</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of biological process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of cellular process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of cell death</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of programmed cell death</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of apoptosis</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Mitochondrion outer membrane</subcellular_location>
    <subcellular_location>Single-pass membrane protein</subcellular_location>
    <subcellular_location>Nucleus membrane</subcellular_location>
    <subcellular_location>Single-pass membrane protein</subcellular_location>
    <subcellular_location>Endoplasmic reticulum membrane</subcellular_location>
    <subcellular_location>Single-pass membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:1</chromosome_location>
    <locus>18q21.33|18q21.3</locus>
    <gene_sequence>&gt;720 bp
ATGGCGCACGCTGGGAGAACAGGGTACGATAACCGGGAGATAGTGATGAAGTACATCCAT
TATAAGCTGTCGCAGAGGGGCTACGAGTGGGATGCGGGAGATGTGGGCGCCGCGCCCCCG
GGGGCCGCCCCCGCACCGGGCATCTTCTCCTCCCAGCCCGGGCACACGCCCCATCCAGCC
GCATCCCGGGACCCGGTCGCCAGGACCTCGCCGCTGCAGACCCCGGCTGCCCCCGGCGCC
GCCGCGGGGCCTGCGCTCAGCCCGGTGCCACCTGTGGTCCACCTGACCCTCCGCCAGGCC
GGCGACGACTTCTCCCGCCGCTACCGCCGCGACTTCGCCGAGATGTCCAGCCAGCTGCAC
CTGACGCCCTTCACCGCGCGGGGACGCTTTGCCACGGTGGTGGAGGAGCTCTTCAGGGAC
GGGGTGAACTGGGGGAGGATTGTGGCCTTCTTTGAGTTCGGTGGGGTCATGTGTGTGGAG
AGCGTCAACCGGGAGATGTCGCCCCTGGTGGACAACATCGCCCTGTGGATGACTGAGTAC
CTGAACCGGCACCTGCACACCTGGATCCAGGATAACGGAGGCTGGGATGCCTTTGTGGAA
CTGTACGGCCCCAGCATGCGGCCTCTGTTTGATTTCTCCTGGCTGTCTCTGAAGACTCTG
CTCAGTTTGGCCCTGGTGGGAGCTTGCATCACCCTGGGTGCCTATCTGGGCCACAAGTGA
</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>239</residue_number>
    <molecular_weight>26265.7</molecular_weight>
    <theoretical_pi>7.32</theoretical_pi>
    <pfams>
      <pfam>
        <name>Bcl-2</name>
        <pfam_id>PF00452</pfam_id>
      </pfam>
      <pfam>
        <name>BH4</name>
        <pfam_id>PF02180</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>212-233</region>
    </transmembrane_regions>
    <signal_regions>
      <region>None</region>
    </signal_regions>
    <protein_sequence>&gt;Apoptosis regulator Bcl-2
MAHAGRTGYDNREIVMKYIHYKLSQRGYEWDAGDVGAAPPGAAPAPGIFSSQPGHTPHPA
ASRDPVARTSPLQTPAAPGAAAGPALSPVPPVVHLTLRQAGDDFSRRYRRDFAEMSSQLH
LTPFTARGRFATVVEELFRDGVNWGRIVAFFEFGGVMCVESVNREMSPLVDNIALWMTEY
LNRHLHTWIQDNGGWDAFVELYGPSMRPLFDFSWLSLKTLLSLALVGACITLGAYLGHK</protein_sequence>
  </protein_properties>
  <genbank_protein_id>28144173</genbank_protein_id>
  <uniprot_id>P10415</uniprot_id>
  <uniprot_name>BCL2_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>AY220759</genbank_gene_id>
  <genecard_id>BCL2</genecard_id>
  <geneatlas_id>BCL2</geneatlas_id>
  <hgnc_id>HGNC:990</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Tsujimoto Y, Croce CM: Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci U S A. 1986 Jul;83(14):5214-8.</reference_text>
      <pubmed_id>3523487</pubmed_id>
    </reference>
    <reference>
      <reference_text>Eguchi Y, Ewert DL, Tsujimoto Y: Isolation and characterization of the chicken bcl-2 gene: expression in a variety of tissues including lymphoid and neuronal organs in adult and embryo. Nucleic Acids Res. 1992 Aug 25;20(16):4187-92.</reference_text>
      <pubmed_id>1508712</pubmed_id>
    </reference>
    <reference>
      <reference_text>Cleary ML, Smith SD, Sklar J: Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell. 1986 Oct 10;47(1):19-28.</reference_text>
      <pubmed_id>2875799</pubmed_id>
    </reference>
    <reference>
      <reference_text>Seto M, Jaeger U, Hockett RD, Graninger W, Bennett S, Goldman P, Korsmeyer SJ: Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J. 1988 Jan;7(1):123-31.</reference_text>
      <pubmed_id>2834197</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hua C, Zorn S, Jensen JP, Coupland RW, Ko HS, Wright JJ, Bakhshi A: Consequences of the t(14;18) chromosomal translocation in follicular lymphoma: deregulated expression of a chimeric and mutated BCL-2 gene. Oncogene Res. 1988 Feb;2(3):263-75.</reference_text>
      <pubmed_id>3285301</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Tanaka S, Louie DC, Kant JA, Reed JC: Frequent incidence of somatic mutations in translocated BCL2 oncogenes of non-Hodgkin's lymphomas. Blood. 1992 Jan 1;79(1):229-37.</reference_text>
      <pubmed_id>1339299</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 1990 Nov 22;348(6299):334-6.</reference_text>
      <pubmed_id>2250705</pubmed_id>
    </reference>
    <reference>
      <reference_text>Yin XM, Oltvai ZN, Korsmeyer SJ: BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature. 1994 May 26;369(6478):321-3.</reference_text>
      <pubmed_id>8183370</pubmed_id>
    </reference>
    <reference>
      <reference_text>Takayama S, Bimston DN, Matsuzawa S, Freeman BC, Aime-Sempe C, Xie Z, Morimoto RI, Reed JC: BAG-1 modulates the chaperone activity of Hsp70/Hsc70.  EMBO J. 1997 Aug 15;16(16):4887-96.</reference_text>
      <pubmed_id>9305631</pubmed_id>
    </reference>
    <reference>
      <reference_text>Cheng EH, Kirsch DG, Clem RJ, Ravi R, Kastan MB, Bedi A, Ueno K, Hardwick JM: Conversion of Bcl-2 to a Bax-like death effector by caspases.  Science. 1997 Dec 12;278(5345):1966-8.</reference_text>
      <pubmed_id>9395403</pubmed_id>
    </reference>
    <reference>
      <reference_text>Naumovski L, Cleary ML: The p53-binding protein 53BP2 also interacts with Bc12 and impedes cell cycle progression at G2/M. Mol Cell Biol. 1996 Jul;16(7):3884-92.</reference_text>
      <pubmed_id>8668206</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ruvolo PP, Deng X, May WS: Phosphorylation of Bcl2 and regulation of apoptosis.  Leukemia. 2001 Apr;15(4):515-22.</reference_text>
      <pubmed_id>11368354</pubmed_id>
    </reference>
    <reference>
      <reference_text>Yamamoto K, Ichijo H, Korsmeyer SJ: BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol. 1999 Dec;19(12):8469-78.</reference_text>
      <pubmed_id>10567572</pubmed_id>
    </reference>
    <reference>
      <reference_text>Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B: PUMA induces the rapid apoptosis of colorectal cancer cells.  Mol Cell. 2001 Mar;7(3):673-82.</reference_text>
      <pubmed_id>11463391</pubmed_id>
    </reference>
    <reference>
      <reference_text>Qin W, Hu J, Guo M, Xu J, Li J, Yao G, Zhou X, Jiang H, Zhang P, Shen L, Wan D, Gu J: BNIPL-2, a novel homologue of BNIP-2, interacts with Bcl-2 and Cdc42GAP in apoptosis. Biochem Biophys Res Commun. 2003 Aug 22;308(2):379-85.</reference_text>
      <pubmed_id>12901880</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kang CB, Tai J, Chia J, Yoon HS: The flexible loop of Bcl-2 is required for molecular interaction with immunosuppressant FK-506 binding protein 38 (FKBP38). FEBS Lett. 2005 Feb 28;579(6):1469-76.</reference_text>
      <pubmed_id>15733859</pubmed_id>
    </reference>
    <reference>
      <reference_text>Chintharlapalli SR, Jasti M, Malladi S, Parsa KV, Ballestero RP, Gonzalez-Garcia M: BMRP is a Bcl-2 binding protein that induces apoptosis.  J Cell Biochem. 2005 Feb 15;94(3):611-26.</reference_text>
      <pubmed_id>15547950</pubmed_id>
    </reference>
    <reference>
      <reference_text>Portier BP, Taglialatela G: Bcl-2 localized at the nuclear compartment induces apoptosis after transient overexpression. J Biol Chem. 2006 Dec 29;281(52):40493-502. Epub 2006 Nov 7.</reference_text>
      <pubmed_id>17090549</pubmed_id>
    </reference>
    <reference>
      <reference_text>Petros AM, Medek A, Nettesheim DG, Kim DH, Yoon HS, Swift K, Matayoshi ED, Oltersdorf T, Fesik SW: Solution structure of the antiapoptotic protein bcl-2.  Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3012-7. Epub 2001 Feb 27.</reference_text>
      <pubmed_id>11248023</pubmed_id>
    </reference>
    <reference>
      <reference_text>Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH: An inhibitor of Bcl-2 family proteins induces regression of solid tumours.  Nature. 2005 Jun 2;435(7042):677-81. Epub 2005 May 15.</reference_text>
      <pubmed_id>15902208</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bruncko M, Oost TK, Belli BA, Ding H, Joseph MK, Kunzer A, Martineau D, McClellan WJ, Mitten M, Ng SC, Nimmer PM, Oltersdorf T, Park CM, Petros AM, Shoemaker AR, Song X, Wang X, Wendt MD, Zhang H, Fesik SW, Rosenberg SH, Elmore SW: Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.  J Med Chem. 2007 Feb 22;50(4):641-62. Epub 2007 Jan 26.</reference_text>
      <pubmed_id>17256834</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Paclitaxel</name>
        <accession>HMDB15360</accession>
      </metabolite>
      <reference>
        <reference_text>Gan Y, Wientjes MG, Au JL: Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors. Pharm Res. 2006 Jun;23(6):1324-31. Epub 2006 Jun 8.</reference_text>
        <pubmed_id>16741658</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paclitaxel</name>
        <accession>HMDB15360</accession>
      </metabolite>
      <reference>
        <reference_text>Thomadaki H, Talieri M, Scorilas A: Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS. Biol Chem. 2006 Aug;387(8):1081-6.</reference_text>
        <pubmed_id>16895478</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paclitaxel</name>
        <accession>HMDB15360</accession>
      </metabolite>
      <reference>
        <reference_text>Yoshino T, Shiina H, Urakami S, Kikuno N, Yoneda T, Shigeno K, Igawa M: Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6116-24.</reference_text>
        <pubmed_id>17062688</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paclitaxel</name>
        <accession>HMDB15360</accession>
      </metabolite>
      <reference>
        <reference_text>Matsuyoshi S, Shimada K, Nakamura M, Ishida E, Konishi N: Bcl-2 phosphorylation has pathological significance in human breast cancer.  Pathobiology. 2006;73(4):205-12.</reference_text>
        <pubmed_id>17119350</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paclitaxel</name>
        <accession>HMDB15360</accession>
      </metabolite>
      <reference>
        <reference_text>Zhang X, Wang Q, Ling MT, Wong YC, Leung SC, Wang X: Anti-apoptotic role of TWIST and its association with Akt pathway in mediating taxol resistance in nasopharyngeal carcinoma cells. Int J Cancer. 2007 May 1;120(9):1891-8.</reference_text>
        <pubmed_id>17230521</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Docetaxel</name>
        <accession>HMDB15378</accession>
      </metabolite>
      <reference>
        <reference_text>Gligorov J, Lotz JP: Preclinical pharmacology of the taxanes: implications of the differences.  Oncologist. 2004;9 Suppl 2:3-8.</reference_text>
        <pubmed_id>15161985</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Docetaxel</name>
        <accession>HMDB15378</accession>
      </metabolite>
      <reference>
        <reference_text>Marshall J, Chen H, Yang D, Figueira M, Bouker KB, Ling Y, Lippman M, Frankel SR, Hayes DF: A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Ann Oncol. 2004 Aug;15(8):1274-83.</reference_text>
        <pubmed_id>15277270</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Docetaxel</name>
        <accession>HMDB15378</accession>
      </metabolite>
      <reference>
        <reference_text>Inoue Y, Gika M, Abiko T, Oyama T, Saitoh Y, Yamazaki H, Nakamura M, Abe Y, Kawamura M, Kobayashi K: Bcl-2 overexpression enhances in vitro sensitivity against docetaxel in non-small cell lung cancer. Oncol Rep. 2005 Feb;13(2):259-64.</reference_text>
        <pubmed_id>15643508</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Docetaxel</name>
        <accession>HMDB15378</accession>
      </metabolite>
      <reference>
        <reference_text>Petrylak DP: Chemotherapy for androgen-independent prostate cancer.  World J Urol. 2005 Feb;23(1):10-3. Epub 2005 Feb 1.</reference_text>
        <pubmed_id>15685445</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Docetaxel</name>
        <accession>HMDB15378</accession>
      </metabolite>
      <reference>
        <reference_text>Miyoshi Y, Uemura H, Kubota Y: [Treatment of androgen-independent hormone refractory prostate cancer using docetaxel]. Nihon Rinsho. 2005 Feb;63(2):298-302.</reference_text>
        <pubmed_id>15714982</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Docetaxel</name>
        <accession>HMDB15378</accession>
      </metabolite>
      <reference>
        <reference_text>Magi-Galluzzi C, Zhou M, Reuther AM, Dreicer R, Klein EA: Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study. Cancer. 2007 Sep 15;110(6):1248-54.</reference_text>
        <pubmed_id>17674353</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rasagiline</name>
        <accession>HMDB15454</accession>
      </metabolite>
      <reference>
        <reference_text>Youdim MB, Weinstock M: Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Cell Mol Neurobiol. 2001 Dec;21(6):555-73.</reference_text>
        <pubmed_id>12043833</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rasagiline</name>
        <accession>HMDB15454</accession>
      </metabolite>
      <reference>
        <reference_text>Akao Y, Maruyama W, Yi H, Shamoto-Nagai M, Youdim MB, Naoi M: An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett. 2002 Jun 28;326(2):105-8.</reference_text>
        <pubmed_id>12057839</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rasagiline</name>
        <accession>HMDB15454</accession>
      </metabolite>
      <reference>
        <reference_text>Maruyama W, Akao Y, Carrillo MC, Kitani K, Youdium MB, Naoi M: Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol. 2002 Sep-Oct;24(5):675-82.</reference_text>
        <pubmed_id>12200198</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rasagiline</name>
        <accession>HMDB15454</accession>
      </metabolite>
      <reference>
        <reference_text>Youdim MB, Amit T, Falach-Yogev M, Bar Am O, Maruyama W, Naoi M: The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline. Biochem Pharmacol. 2003 Oct 15;66(8):1635-41.</reference_text>
        <pubmed_id>14555244</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rasagiline</name>
        <accession>HMDB15454</accession>
      </metabolite>
      <reference>
        <reference_text>Bar-Am O, Weinreb O, Amit T, Youdim MB: Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J. 2005 Nov;19(13):1899-901. Epub 2005 Sep 7.</reference_text>
        <pubmed_id>16148027</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
